Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Current standard of adjuvant therapy in kidney cancer

Pavlos Msaouel • 3 Jun 2022
ASCO 2022
Genitourinary Cancer Kidney Cancer Antibodies Pembrolizumab Sunitinib

Pavlos Msaouel, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of the standard for adjuvant therapy of kidney cancer, including sunitinib as well as the more recent use of pembrolizumab which was approved based on the results of the a KEYNOTE-564 (NCT03142334). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Pavlos Msaouel

1:59
Key objectives in kidney cancer: treatment sequencing & refining clinical endpoints
Pavlos Msaouel • 3 Jun 2022
2:50
Sitravatinib and nivolumab in ccRCC following progression on antiangiogenic therapy
Pavlos Msaouel • 3 Jun 2022
2:35
Adjuvant therapy in RCC: harnessing prognostic information
Pavlos Msaouel • 3 Jun 2022
4:08
Bevacizumab plus erlotinib for RMC
Pavlos Msaouel • 4 Feb 2021

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals